Exudate Solution


Every moment matters when it comes to a quick and effective exudate solution for venous leg ulcers.
Leg ulcers
The reality today

Leg ulcers affect a large number of patients, many of whom will suffer from recurring symptoms. It’s therefore essential that we look for ways to enable patients to manage and care for themselves, to promote their independence and reduce the hours spent on care whilst improving outcomes.

- **730,000 patients affected**
  There are currently 730,000 patients in the UK suffering from leg ulcers. With an aging population, this number is only likely to rise.¹

- **1.5% of the adult population**
  Leg ulcers affect 1.5% of adults and can have a significant impact on a patient’s quality of life.¹

- **26-69% recurrence rate**
  Venous leg ulcers have a high recurrence rate, making management and prevention a top priority.¹

Impact
To the NHS

The NHS has set big goals for 2020 and, as a key decision maker, you have the opportunity to make changes today that will benefit our healthcare system tomorrow.

- **NHS 2020**
  The NHS has stated that it needs to save £20 billion by 2020 as part of its 5-year forward view.

- **£1.94 billion**
  This is how much it costs the NHS to manage leg ulcers each year, impacting overall healthcare budgets and society as a whole.²

- **6,294,190**
  Superabsorbent dressings were prescribed nationally in 2017.³

Different thinking is needed if we’re going to reach NHS targets.
How exudate impacts patients

• Saturated dressings can become malodorous
• Leakage and strikethrough causes embarrassment
• Makes patients feel unclean
• Patients isolate themselves from social situations
• Can lead to low self-esteem and even depression
• Physical presence of exudate and malodour is a constant reminder to the patient that they are living with a wound

Best Practice Statement: Effective Exudate Management (Wounds UK, 2013)

Every moment matters to clinicians and patients

While the saying ‘time is a great healer’ might be true for some conditions, when it comes to leg ulcers, every moment matters.

Managing highly exuding leg ulcers
Higher than normal exudate levels in leg ulcers can be caused by oedema, systemic or local infection or increased devitalised tissue or slough. It is important to address the underlying factors affecting exudate production as well as managing the exudate itself. By implementing a structured solution straight away patients can move out of the inflammatory stage of healing as quickly as possible.
Our mission
We aim to support the NHS in three key areas

Our mission at L&R is to support healthcare organisations in adopting the key principles of the Best Practice Statement, including the Leg Ulcer Treatment Algorithm, in order to improve clinical outcomes and patient experience.

- Driving the timely assessment of leg ulcers to prevent chronicity and improve outcomes.
- Enabling rapid and safe debridement to facilitate healing, while improving dressing selection.
- Supporting safe, clinically proven and cost-effective compression selection.

The L&R Solution

Every moment matters when it comes to a quick and effective exudate solution for venous leg ulcers.

The L&R Exudate Solution for venous leg ulcers has been developed to greatly reduce levels of exudate, (Atkin and Tickle 2016; Wounds UK 2016) to speed up the patient’s journey through the leg ulcer treatment algorithm and enable them to move towards healing wearing a hosiery kit. This enables better patient and health economic outcomes, (Ashby et al. 2014).

Use our effective 3 step method…..

1. Is the exudate controlled within topical dressing?
2. Apply Activa® leg ulcer hosiery kit or Actilymph® hosiery kit
Debrisoft®
Remove barriers to healing

Slough and devitalised tissue can significantly increase exudate levels as the body produces more in order to autolytically debride. Using Debrisoft® removes the reason for this process and prepares the wound bed for healing.

The Debrisoft® Difference
*The Debrisoft® Difference Challenge® surveyed over 4,000 nurses to gather information on debridement practice in the UK and the effectiveness of Debrisoft®. The research reported overwhelmingly positive results:

- **94%** Saw a change in the wound after only two weeks of treatment.
- **77%** Reported a reduction in the production of exudate.
- **83%** Reported no local signs of infection.

Debrisoft®

Did you know?
During complete debridement, the Debrisoft® pad is estimated to reduce costs when compared with other debridement methods, (NICE, 2014).

Cost saving per patient when using Debrisoft® versus autolytic debridement:

<table>
<thead>
<tr>
<th></th>
<th>In a community clinic</th>
<th>In a home</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autolytic debridement*</td>
<td>£99</td>
<td>£222</td>
</tr>
</tbody>
</table>

*Based on hydrogels

The likely benefits of using the Debrisoft® pad on appropriate wounds are that they will be fully debrided more quickly, with fewer nurse visits needed, compared with other debridement methods, (NICE, 2014).

Recommended by NICE National Institute for Health and Care Excellence
Vliwasorb® Pro
Dressing for highly exuding wounds

The new spherical structure of the polymers provide greater surface area, giving Vliwasorb® Pro greater absorbency capacity than Flivasorb®.

- **Effective exudate management**
  Very high absorbency and retention capacity means longer dressing change intervals - saving time and money, with less disturbance of the wound.

- **Comfort and conformability**
  New ergonomic shape, flexible design and softer absorbent core is easy to retain and comfortable for patients to wear.

- **Locks away harmful proteases and bacteria**
  Proteases and microbes are bound in the superabsorbent polymer core which reduces the microbial burden and odours.

Vliwasorb® Pro
For your budget

**Did you know?**
Vliwasorb® Pro may be used as a primary wound dressing - it’s integrated wound contact layer negates the need to use an additional contact layer underneath - saving budget.

<table>
<thead>
<tr>
<th></th>
<th>Kerramax Care™ and Atrauman™</th>
<th>Vliwasorb® Pro</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total dressings cost</strong></td>
<td>£5.61&lt;sup&gt;7&lt;/sup&gt;</td>
<td>£2.37&lt;sup&gt;7&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Not only does Vliwasorb® Pro present an immediate cost saving, clinicians have also stated that the frequency of dressing changes also reduced when using Vliwasorb® Pro.<sup>8</sup>
Actico®
Compress to heal

For the treatment and management of venous leg ulcers, especially where exudate or oedema are a challenge, Actico® will promote venous return, reducing exudate and promoting leg ulcer healing.9

Actico® will deliver therapeutic working and tolerable resting pressures to mimic a healthy working vascular system. This improves patient comfort and concordance, allowing them to get on with their lives.

Change in practice to follow the L&R exudate solution will get patients into self-care solutions, such as a hosiery kit or ReadyWrap® quicker, allowing clinicians to help more patients on their way to healing.

In line with best practice10, once exudate levels have reduced step your patient down to a Leg Ulcer Hosiery Kit until healed.

Actico®
For your budget

Why pay more? When your patient’s legs are being managed with compression bandaging, make sure you’re using the most cost effective option.

<table>
<thead>
<tr>
<th>Bandage System</th>
<th>Ankle Circumference of 18-25cm</th>
<th>Ankle Circumference of 25-32cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>K-Two®</td>
<td>£65.927</td>
<td>£727</td>
</tr>
<tr>
<td>Actico® + Cellona® Under Cast Padding11</td>
<td>£31.047</td>
<td>£58.327</td>
</tr>
</tbody>
</table>

Based upon twice weekly bandage changes over a 4 week period.
Once the exudate levels have been reduced to low to moderate, refer to the Best Practice Statement for the Holistic Management of Venous Leg Ulceration and move the patient across to an Activa® Leg Ulcer Hosiery kit for limbs without oedema, an ActiLymph® Leg Ulcer Hosiery kit for limbs with Oedema, or ReadyWrap™ for limbs with a large amount of reducible Oedema and/or limb distortion.
References


7. April 2018 Drug Tariff pricing, Kerramax Care™ superabsorbent dressing (20 x 30cm), Atrauman® wound contact layer (20 x 30cm), Vliwasorb® Pro (22 x 32cm). UrgoK-Two multi layer compression bandage kit 18-25cm & 25cm-30cm.


11. Ankle circumference of 18-25cm - 1 x Actico® 10cm plus 1 x 10xm Cellona® Undercast Padding.
   Ankle circumference of 25-32cm - 2 x Actico® 10cm plus 1 x 10xm Cellona® Undercast Padding.

<table>
<thead>
<tr>
<th>Product</th>
<th>Size</th>
<th>Pip Code</th>
<th>NHS Supply Chain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debrisoft (5 pieces)</td>
<td>10cm x 10cm</td>
<td>358-1287</td>
<td>ELZ963</td>
</tr>
<tr>
<td>Debrisoft Lolly (5 pieces)</td>
<td>5cm x 1.9cm</td>
<td>398-5124</td>
<td>ELZ728</td>
</tr>
<tr>
<td>Vliwasorb Pro Superabsorbent (10 Singles)</td>
<td>12.5cm x 12.5cm</td>
<td>399-9893</td>
<td>EJA218</td>
</tr>
<tr>
<td>Vliwasorb Pro Superabsorbent (10 Singles)</td>
<td>12.5cm x 22.5cm</td>
<td>399-9901</td>
<td>EJA219</td>
</tr>
<tr>
<td>Vliwasorb Pro Superabsorbent (10 Singles)</td>
<td>22cm x 22cm</td>
<td>399-9919</td>
<td>EJA220</td>
</tr>
<tr>
<td>Vliwasorb Pro Superabsorbent (10 Singles)</td>
<td>22cm x 32cm</td>
<td>399-9927</td>
<td>EJA221</td>
</tr>
<tr>
<td>Actico</td>
<td>10cm x 6cm</td>
<td>271-5431</td>
<td>EBA016</td>
</tr>
<tr>
<td>Cellona Undercast Padding</td>
<td>10cm x 2.7cm</td>
<td>214-5860</td>
<td>EPA035</td>
</tr>
</tbody>
</table>

Actico® is registered to L&R Medical UK Ltd, formerly known as Activa Healthcare Ltd. Debrisoft®, Vliwasorb® Pro and Flivasorb® are registered trademarks of L&R. KerraMax Care™ is a trademark of Crawford Healthcare Limited. Atrauman® is registered to the Hartmann Group. Coban™ is a trademark of the 3M Company. KTwo® is registered to Urgo Medical Limited.

Call our Customer Care line: 08450 606707 or visit our website at: www.Lohmann-Rauscher.co.uk

Actico® is registered to L&R Medical UK Ltd, formerly known as Activa Healthcare Ltd. Debrisoft®, Vliwasorb® Pro and Flivasorb® are registered trademarks of L&R. KerraMax Care™ is a trademark of Crawford Healthcare Limited. Atrauman® is registered to the Hartmann Group. Coban™ is a trademark of the 3M Company. KTwo® is registered to Urgo Medical Limited.